Research ArticleAccepted Article
Evaluation and validation of a patient completed psoriatic arthritis flare questionnaire
Philip S. Helliwell, William Tillett, Robin Waxman, Laura C. Coates, Mel Brooke, Oliver FitzGerald, Jonathan C. Packham and Neil McHugh on behalf of the PROMPT study group
The Journal of Rheumatology February 2021, jrheum.201317; DOI: https://doi.org/10.3899/jrheum.201317
Philip S. Helliwell
Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust Department of Pharmacy and Pharmacology, University of Bath, UK; Royal National Hospital for Rheumatic Diseases, Royal United Hospitals, Bath, UK; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, UK; Conway Institute for Biomolecular Research, University College Dublin (UCD), Dublin, Ireland; Division of Epidemiology and Public of Health, University of Nottingham, UK. This report is independent research funded by the National Institute for Health Research, Programme Grants for Applied Research [Early detection to improve outcome in patients with undiagnosed PsA (‘PROMPT’), RP-PG-1212-20007]. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. Address correspondence to Dr Philip Helliwell, LIRMM, Chapel Allerton Hospital, Chapeltown Road, Leeds LS7 4SA, UK. Email: p.helliwell@leeds.ac.uk
William Tillett
Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust Department of Pharmacy and Pharmacology, University of Bath, UK; Royal National Hospital for Rheumatic Diseases, Royal United Hospitals, Bath, UK; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, UK; Conway Institute for Biomolecular Research, University College Dublin (UCD), Dublin, Ireland; Division of Epidemiology and Public of Health, University of Nottingham, UK. This report is independent research funded by the National Institute for Health Research, Programme Grants for Applied Research [Early detection to improve outcome in patients with undiagnosed PsA (‘PROMPT’), RP-PG-1212-20007]. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. Address correspondence to Dr Philip Helliwell, LIRMM, Chapel Allerton Hospital, Chapeltown Road, Leeds LS7 4SA, UK. Email: p.helliwell@leeds.ac.uk
Robin Waxman
Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust Department of Pharmacy and Pharmacology, University of Bath, UK; Royal National Hospital for Rheumatic Diseases, Royal United Hospitals, Bath, UK; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, UK; Conway Institute for Biomolecular Research, University College Dublin (UCD), Dublin, Ireland; Division of Epidemiology and Public of Health, University of Nottingham, UK. This report is independent research funded by the National Institute for Health Research, Programme Grants for Applied Research [Early detection to improve outcome in patients with undiagnosed PsA (‘PROMPT’), RP-PG-1212-20007]. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. Address correspondence to Dr Philip Helliwell, LIRMM, Chapel Allerton Hospital, Chapeltown Road, Leeds LS7 4SA, UK. Email: p.helliwell@leeds.ac.uk
Laura C. Coates
Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust Department of Pharmacy and Pharmacology, University of Bath, UK; Royal National Hospital for Rheumatic Diseases, Royal United Hospitals, Bath, UK; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, UK; Conway Institute for Biomolecular Research, University College Dublin (UCD), Dublin, Ireland; Division of Epidemiology and Public of Health, University of Nottingham, UK. This report is independent research funded by the National Institute for Health Research, Programme Grants for Applied Research [Early detection to improve outcome in patients with undiagnosed PsA (‘PROMPT’), RP-PG-1212-20007]. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. Address correspondence to Dr Philip Helliwell, LIRMM, Chapel Allerton Hospital, Chapeltown Road, Leeds LS7 4SA, UK. Email: p.helliwell@leeds.ac.uk
Mel Brooke
Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust Department of Pharmacy and Pharmacology, University of Bath, UK; Royal National Hospital for Rheumatic Diseases, Royal United Hospitals, Bath, UK; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, UK; Conway Institute for Biomolecular Research, University College Dublin (UCD), Dublin, Ireland; Division of Epidemiology and Public of Health, University of Nottingham, UK. This report is independent research funded by the National Institute for Health Research, Programme Grants for Applied Research [Early detection to improve outcome in patients with undiagnosed PsA (‘PROMPT’), RP-PG-1212-20007]. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. Address correspondence to Dr Philip Helliwell, LIRMM, Chapel Allerton Hospital, Chapeltown Road, Leeds LS7 4SA, UK. Email: p.helliwell@leeds.ac.uk
Oliver FitzGerald
Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust Department of Pharmacy and Pharmacology, University of Bath, UK; Royal National Hospital for Rheumatic Diseases, Royal United Hospitals, Bath, UK; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, UK; Conway Institute for Biomolecular Research, University College Dublin (UCD), Dublin, Ireland; Division of Epidemiology and Public of Health, University of Nottingham, UK. This report is independent research funded by the National Institute for Health Research, Programme Grants for Applied Research [Early detection to improve outcome in patients with undiagnosed PsA (‘PROMPT’), RP-PG-1212-20007]. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. Address correspondence to Dr Philip Helliwell, LIRMM, Chapel Allerton Hospital, Chapeltown Road, Leeds LS7 4SA, UK. Email: p.helliwell@leeds.ac.uk
Jonathan C. Packham
Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust Department of Pharmacy and Pharmacology, University of Bath, UK; Royal National Hospital for Rheumatic Diseases, Royal United Hospitals, Bath, UK; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, UK; Conway Institute for Biomolecular Research, University College Dublin (UCD), Dublin, Ireland; Division of Epidemiology and Public of Health, University of Nottingham, UK. This report is independent research funded by the National Institute for Health Research, Programme Grants for Applied Research [Early detection to improve outcome in patients with undiagnosed PsA (‘PROMPT’), RP-PG-1212-20007]. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. Address correspondence to Dr Philip Helliwell, LIRMM, Chapel Allerton Hospital, Chapeltown Road, Leeds LS7 4SA, UK. Email: p.helliwell@leeds.ac.uk
Neil McHugh
Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust Department of Pharmacy and Pharmacology, University of Bath, UK; Royal National Hospital for Rheumatic Diseases, Royal United Hospitals, Bath, UK; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, UK; Conway Institute for Biomolecular Research, University College Dublin (UCD), Dublin, Ireland; Division of Epidemiology and Public of Health, University of Nottingham, UK. This report is independent research funded by the National Institute for Health Research, Programme Grants for Applied Research [Early detection to improve outcome in patients with undiagnosed PsA (‘PROMPT’), RP-PG-1212-20007]. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. Address correspondence to Dr Philip Helliwell, LIRMM, Chapel Allerton Hospital, Chapeltown Road, Leeds LS7 4SA, UK. Email: p.helliwell@leeds.ac.uk
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Accepted manuscript
Evaluation and validation of a patient completed psoriatic arthritis flare questionnaire
Philip S. Helliwell, William Tillett, Robin Waxman, Laura C. Coates, Mel Brooke, Oliver FitzGerald, Jonathan C. Packham, Neil McHugh
The Journal of Rheumatology Feb 2021, jrheum.201317; DOI: 10.3899/jrheum.201317
Accepted manuscript
Evaluation and validation of a patient completed psoriatic arthritis flare questionnaire
Philip S. Helliwell, William Tillett, Robin Waxman, Laura C. Coates, Mel Brooke, Oliver FitzGerald, Jonathan C. Packham, Neil McHugh
The Journal of Rheumatology Feb 2021, jrheum.201317; DOI: 10.3899/jrheum.201317